Literature DB >> 9749453

Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them.

G G Koch1, C M Tangen, J W Jung, I A Amara.   

Abstract

Analysis of covariance is an effective method for addressing two considerations for randomized clinical trials. One is reduction of variance for estimates of treatment effects and thereby the production of narrower confidence intervals and more powerful statistical tests. The other is the clarification of the magnitude of treatment effects through adjustment of corresponding estimates for any random imbalances between the treatment groups with respect to the covariables. The statistical basis of covariance analysis can be either non-parametric, with reliance only on the randomization in the study design, or parametric through a statistical model for a postulated sampling process. For non-parametric methods, there are no formal assumptions for how a response variable is related to the covariables, but strong correlation between response and covariables is necessary for variance reduction. Computations for these methods are straightforward through the application of weighted least squares to fit linear models to the differences between treatment groups for the means of the response variable and the covariables jointly with a specification that has null values for the differences that correspond to the covariables. Moreover, such analysis is similarly applicable to dichotomous indicators, ranks or integers for ordered categories, and continuous measurements. Since non-parametric covariance analysis can have many forms, the ones which are planned for a clinical trial need careful specification in its protocol. A limitation of non-parametric analysis is that it does not directly address the magnitude of treatment effects within subgroups based on the covariables or the homogeneity of such effects. For this purpose, a statistical model is needed. When the response criterion is dichotomous or has ordered categories, such a model may have a non-linear nature which determines how covariance adjustment modifies results for treatment effects. Insight concerning such modifications can be gained through their evaluation relative to non-parametric counterparts. Such evaluation usually indicates that alternative ways to compare treatments for a response criterion with adjustment for a set of covariables mutually support the same conclusion about the strength of treatment effects. This robustness is noteworthy since the alternative methods for covariance analysis have substantially different rationales and assumptions. Since findings can differ in important ways across alternative choices for covariables (as opposed to methods for covariance adjustment), the critical consideration for studies with covariance analyses planned as the primary method for comparing treatments is the specification of the covariables in the protocol (or in an amendment or formal plan prior to any unmasking of the study.

Mesh:

Year:  1998        PMID: 9749453     DOI: 10.1002/(sici)1097-0258(19980815/30)17:15/16<1863::aid-sim989>3.0.co;2-m

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  32 in total

1.  On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial.

Authors:  Lu Tian; Tianxi Cai; Lihui Zhao; Lee-Jen Wei
Journal:  Biostatistics       Date:  2012-01-30       Impact factor: 5.899

2.  Energy intake and expenditure during sedentary screen time and motion-controlled video gaming.

Authors:  Elizabeth J Lyons; Deborah F Tate; Dianne S Ward; Xiaoshan Wang
Journal:  Am J Clin Nutr       Date:  2012-07-03       Impact factor: 7.045

3.  Robust extraction of covariate information to improve estimation efficiency in randomized trials.

Authors:  Kelly L Moore; Romain Neugebauer; Thamban Valappil; Mark J Laan
Journal:  Stat Med       Date:  2011-07-12       Impact factor: 2.373

4.  Semiparametric Estimation of Treatment Effect in a Pretest-Posttest Study with Missing Data.

Authors:  Marie Davidian; Anastasios A Tsiatis; Selene Leon
Journal:  Stat Sci       Date:  2005-08       Impact factor: 2.901

5.  Applying permutation tests with adjustment for covariates and attrition weights to randomized trials of health-services interventions.

Authors:  Lingqi Tang; Naihua Duan; Ruth Klap; Joan Rosenbaum Asarnow; Thomas R Belin
Journal:  Stat Med       Date:  2009-01-15       Impact factor: 2.373

6.  Efficiency improvement in a class of survival models through model-free covariate incorporation.

Authors:  Tanya P Garcia; Yanyuan Ma; Guosheng Yin
Journal:  Lifetime Data Anal       Date:  2011-04-01       Impact factor: 1.588

7.  Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Authors:  Martin R Farlow; Stephen Salloway; Pierre N Tariot; Jane Yardley; Margaret L Moline; Qin Wang; Elimor Brand-Schieber; Heng Zou; Timothy Hsu; Andrew Satlin
Journal:  Clin Ther       Date:  2010-07       Impact factor: 3.393

8.  Progression of Fatty Muscle Degeneration in Atraumatic Rotator Cuff Tears.

Authors:  Jonah Hebert-Davies; Sharlene A Teefey; Karen Steger-May; Aaron M Chamberlain; William Middleton; Kathryn Robinson; Ken Yamaguchi; Jay D Keener
Journal:  J Bone Joint Surg Am       Date:  2017-05-17       Impact factor: 5.284

9.  An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke.

Authors:  Pitchaiah Mandava; Shreyansh D Shah; Anand K Sarma; Thomas A Kent
Journal:  Transl Stroke Res       Date:  2015-09-19       Impact factor: 6.829

10.  A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data.

Authors:  Benjamin R Saville; Amy H Herring; Gary G Koch
Journal:  Stat Med       Date:  2010-01-15       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.